In a significant development for cancer treatment, Sonire Therapeutics has been selected for the New Energy and Industrial Technology Development Organization’s (NEDO) Deep-Tech Startups Support Program. This prestigious initiative, one of Japan’s largest government-backed programs, aims to accelerate the commercialization of innovative technologies. Sonire Therapeutics KK, the Japan-based subsidiary of the U.S. company, will receive approximately $13 million in non-dilutive funding to advance its proprietary High-Intensity Focused Ultrasound (HIFU) therapy platform.
The funding will be instrumental in scaling up manufacturing, obtaining regulatory approvals in Japan, expanding into new clinical indications, and accelerating ongoing clinical development efforts in the United States. This award underscores the potential of Sonire’s technology and its global commercialization strategy, bridging the gap between development and market adoption.
Advancing Cancer Treatment with HIFU Technology
Sonire’s next-generation HIFU therapy system represents a leap forward in cancer treatment. By leveraging real-time ultrasound guidance, the system delivers precise, non-invasive tumor ablation. This innovative approach allows physicians to monitor treatment as it is administered, eliminating the need for general anesthesia. The procedure is designed to reduce the burden on patients and expand access to pancreatic cancer treatment in outpatient settings, addressing a critical unmet need in a disease with a five-year survival rate of approximately 13 percent.
Recent Milestones and Future Prospects
The NEDO award is the latest in a series of significant achievements for Sonire Therapeutics. The company has recently initiated the SUNRISE-II clinical trial in the U.S., secured $18 million in Series A financing, and completed patient enrollment in the SUNRISE-I trial in Japan. These milestones highlight the growing momentum behind Sonire’s technology and its potential to transform oncology.
Sonire has previously advanced through the STS and PCA phases of the NEDO DTSU Program. The current DMP phase represents the program’s most advanced commercialization stage, supporting manufacturing readiness and market preparation activities. By providing comprehensive support across development, regulatory approval, manufacturing, and commercialization, the program positions Sonire to accelerate the global adoption of its ultrasound-guided HIFU technology.
This funding will not only expedite clinical development and regulatory activities but also enhance manufacturing readiness and commercialization efforts in both Japan and the United States. By making this technology available to patients worldwide, Sonire Therapeutics is poised to make a significant impact on the future of cancer treatment.
